United Therapeutics CorporationUTHRNASDAQ

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 68% recommend buying.

Consensus Rating

Buy

22 analysts·High coverage

68%

Rating Distribution

Strong Buy

00%

Buy

1568%

Hold

627%

Sell

15%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 18% higher.

Bear Case

$447.00

-4%

Consensus

$550.67

+18%

Bull Case

$645.00

+39%

Price Range22 analysts

Low

Consensus

High

$447.00

$645.00

Current Target

Current Price

$464.93

Upside to Target

$85.74

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$30.50(11 analysts)

P/E16x

Current: 16.0x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+9.92%

EPS+6.84%

FY2028

Rev+14.95%

EPS+25.81%

FY2029

Rev+14.39%

EPS+15.48%

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:-1.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 6, 2026UBS

United Therapeutics price target raised to $645 from $600 at UBS

Target:$645.00

+27.3%from $506.79

Nov 19, 2025Jefferies

Jefferies Reiterates Buy Rating on United Therapeutics Corp. (UTHR)

Target:$575.00

+20.6%from $476.59

Oct 30, 2025H.C. Wainwright

United Therapeutics price target raised to $525 from $500 at H.C. Wainwright

Target:$525.00

+16.7%from $449.76

Oct 30, 2025RBC Capital

United Therapeutics price target raised to $587 from $569 at RBC Capital

Target:$587.00

+30.5%from $449.76

Oct 29, 2025Morgan Stanley

United Therapeutics (UTHR) PT Raised to $447 at Morgan Stanley

Target:$447.00

-0.6%from $449.70

Oct 10, 2025Morgan Stanley

United Therapeutics price target raised to $435 from $328 at Morgan Stanley

Target:$435.00

-2.3%from $445.38

Sep 29, 2025UBS

United Therapeutics price target raised to $580 from $560 at UBS

Target:$580.00

+34.1%from $432.66

Sep 26, 2025RBC Capital

United Therapeutics initiated with an Outperform at RBC Capital

Target:$569.00

+33.2%from $427.15

Sep 10, 2025Cantor Fitzgerald

United Therapeutics price target raised to $525 from $405 at Cantor Fitzgerald

Target:$525.00

+32.4%from $396.50

Sep 5, 2025H.C. Wainwright

United Therapeutics price target raised to $500 from $400 at H.C. Wainwright

Target:$500.00

+24.8%from $400.52

Sep 2, 2025Jefferies

United Therapeutics price target raised to $564 from $432 at Jefferies

Target:$564.00

+39.3%from $404.81

Jul 31, 2025H.C. Wainwright

United Therapeutics Corp. (UTHR) PT Lowered to $400 at H.C. Wainwright

Target:$400.00

+41.9%from $281.95

Apr 25, 2025Wells Fargo

Wells Fargo downgrades United Therapeutics on IPF data concerns

Target:$314.00

+7.8%from $291.38

Oct 31, 2024Argus Research

United Therapeutics price target raised to $400 from $360 at Argus

Target:$400.00

+10.4%from $362.36

Oct 31, 2024H.C. Wainwright

United Therapeutics Corp. (UTHR) PT Raised to $425 at H.C. Wainwright

Target:$425.00

+17.6%from $361.40

Sep 23, 2024Jefferies

United Therapeutics Corp. (UTHR) PT Raised to $432 at Jefferies

Target:$432.00

+22.4%from $353.00

Aug 28, 2024Oppenheimer

United Therapeutics Corp. (UTHR) PT Raised to $575 at Oppenheimer

Target:$575.00

+58.6%from $362.44

Jul 8, 2024UBS

United Therapeutics Corp. (UTHR) PT Raised to $370 at UBS

Target:$370.00

+16.7%from $317.18

Jun 12, 2024Wells Fargo

United Therapeutics price target raised to $350 from $325 at Wells Fargo

Target:$350.00

+26.9%from $275.76

May 2, 2024Oppenheimer

United Therapeutics price target raised to $400 from $375 at Oppenheimer

Target:$400.00

+56.8%from $255.14

Feb 12, 2024Goldman Sachs

This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate

Target:$215.00

+0.1%from $214.74

Jan 11, 2023Argus Research

Argus Research Maintains Buy on United Therapeutics, Raises Price Target to $300

Target:$300.00

+13.9%from $263.41

Dec 6, 2022Morgan Stanley

Morgan Stanley Maintains Overweight on United Therapeutics, Raises Price Target to $330

Target:$330.00

+19.5%from $276.07

Dec 6, 2022UBS

UBS Initiates Coverage On United Therapeutics with Buy Rating, Announces Price Target of $320

Target:$320.00

+16.9%from $273.72

Dec 5, 2022Goldman Sachs

Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $230

Target:$230.00

-17.4%from $278.55

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance